StockMarketWire.com - Animal pharmaceuticals company Animalcare Group said it had received a positive opinion from European regulators for its dermatology product Cortacare.

The Committee for Medicinal Products for Veterinary Use had recommended European marketing authorisation for the product, which Animalcare planned to launch in the fourth quarter of 2018.

Cortacare was a wholly-owned product, developed by Animalcare as a cutaneous spray for the treatment of inflammatory and pruritic dermatitis in dogs.

'As part of the reprioritisation of our product development pipeline we identified 17 core development products,' chief executive Chris Cardon said.

'We are pleased to see the first of these receive a positive recommendation from the CVMP, which paves the way for the commercialisation of this product across Europe and expands our existing dermatology portfolio.'


At 1:43pm: [LON:ANCR] Animalcare Group PLC share price was -0.5p at 156.5p



Story provided by StockMarketWire.com